Carbidopa; levodopa - Generic Drug Details

What are the generic sources for carbidopa; levodopa and what is the scope of patent protection?

Carbidopa; levodopa is the generic ingredient in nine branded drugs marketed by Impax, Abbvie, Accord Hlthcare, Alembic, Apotex, Impax Labs, Kv Pharm, Mylan, Rubicon Research, Sciegen Pharms, Sun Pharm Inds, Organon Llc, Ranbaxy, Rising, Sun Pharm, Ucb Inc, Actavis Elizabeth, Ani Pharms, Apotex Inc, Ascent Pharms Inc, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Pharmobedient, SCS, Watson Labs, Zydus Pharms, Avion Pharms, and Organon, and is included in thirty-seven NDAs. There are forty patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Carbidopa; levodopa has sixty-five patent family members in fifteen countries.

Thirty-seven suppliers are listed for this compound.

Summary for carbidopa; levodopa

International Patents:	65
US Patents:	40
Tradenames:	9
Applicants:	28
NDAs:	37
Finished Product Suppliers / Packagers:	37
Clinical Trials:	192
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for carbidopa; levodopa
DailyMed Link:	carbidopa; levodopa at DailyMed

Recent Clinical Trials for carbidopa; levodopa

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Cleveland Clinic	PHASE4
Julien Bally	PHASE1
Amneal Pharmaceuticals, LLC	PHASE4

See all carbidopa; levodopa clinical trials

Pharmacology for carbidopa; levodopa

Drug Class

Aromatic Amino Acid

Anatomical Therapeutic Chemical (ATC) Classes for carbidopa; levodopa

N04BA	Dopa and dopa derivatives
N04B	DOPAMINERGIC AGENTS
N04	ANTI-PARKINSON DRUGS
N	Nervous system

Paragraph IV (Patent) Challenges for CARBIDOPA; LEVODOPA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CREXONT	Extended-release Capsules	carbidopa; levodopa	35 mg/140 mg 52.5 mg/210 mg 70 mg/280 mg 87.5 mg/350 mg	217186	1	2024-09-23
RYTARY	Extended-release Capsules	carbidopa; levodopa	23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg	203312	1	2015-06-24
RYTARY	Extended-release Capsules	carbidopa; levodopa	61.25 mg/245 mg	203312	1	2015-06-10

US Patents and Regulatory Information for carbidopa; levodopa

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sciegen Pharms	CARBIDOPA AND LEVODOPA	carbidopa; levodopa	TABLET;ORAL	214092-002	May 7, 2021	AB	RX	No	No
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes	8,454,998		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No	9,901,640		Y
Zydus Pharms	CARBIDOPA AND LEVODOPA	carbidopa; levodopa	TABLET;ORAL	215999-003	Apr 4, 2023		DISCN	No	No
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-001	Aug 7, 2024		RX	Yes	No	11,622,941		Y
Impax	CREXONT	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	217186-003	Aug 7, 2024		RX	Yes	No

Expired US Patents for carbidopa; levodopa

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Llc	SINEMET CR	carbidopa; levodopa	TABLET, EXTENDED RELEASE;ORAL	019856-002	Dec 24, 1992	4,832,957
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-002	Jan 7, 2015	7,094,427
Organon Llc	SINEMET CR	carbidopa; levodopa	TABLET, EXTENDED RELEASE;ORAL	019856-001	May 30, 1991	3,830,827
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-001	Jan 7, 2015	7,094,427
Organon Llc	SINEMET CR	carbidopa; levodopa	TABLET, EXTENDED RELEASE;ORAL	019856-002	Dec 24, 1992	4,900,755
Organon	SINEMET	carbidopa; levodopa	TABLET;ORAL	017555-001	Approved Prior to Jan 1, 1982	3,830,827

EU/EMA Drug Approvals for carbidopa; levodopa

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Amneal Pharma Europe Ltd	Numient	levodopa, carbidopa	EMEA/H/C/002611Symptomatic treatment of adult patients with Parkinson’s disease	Withdrawn	no	no	no	2015-11-19

International Patents for carbidopa; levodopa

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009085306
Japan	2017014295	レボドパの放出制御製剤及びその使用 (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)
China	116801869
China	101910113	Controlled release formulations of levodopa and uses thereof
Japan	6898375
Japan	2016532655	レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用

Supplementary Protection Certificates for carbidopa; levodopa

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3209302	2390502-9	Sweden		PRODUCT NAME: FOSLEVODOPA/FOSCARBIDOPA; NAT. REG. NO/DATE: MTNR 62386 20220912; FIRST REG.: AT 141371 20220826

Carbidopa; levodopa Market Analysis and Financial Projection

Last updated: February 14, 2026

Market dynamics and financial trajectory for CARBIDOPA; LEVODOPA

Summary:
Carbidopa/Levodopa remains a cornerstone in Parkinson’s disease (PD) management, experiencing steady demand due to its established efficacy. The market's growth forecasts are robust, driven by rising PD prevalence, ongoing patent expirations, and increasing adoption of combination therapies. Investment in R&D continues, with generics and biosimilars expanding access, impacting pricing dynamics and profit margins.

---

How does the global Parkinson’s disease market drive demand for Carbidopa/Levodopa?

The increasing prevalence of Parkinson’s disease, projected to reach 12 million globally by 2040, largely fuels demand. Age-related demographics and improved diagnostics contribute to rising prescriptions. Currently, the drug maintains over $2 billion in annual sales, primarily in North America and Europe.

What are the key market players and competitive landscape?

Major pharmaceutical companies include:

• AbbVie: North American leader with brands like Sinemet.
• Zynerba Pharmaceuticals: Developing alternative formulations.
• Teva Pharmaceuticals: Produces generic versions.

Patent expirations, notably for Sinemet, have led to proliferation of generics. The generic segment now accounts for approximately 70% of the market, pressuring branded prices.

How do regulatory policies influence market trajectory?

Regulatory decisions impact drug availability and market share:

• FDA approvals: Favor generics with streamlined pathways.
• Pricing policies: In the US, Medicare and Medicaid negotiations exert downward pressure.
• International regulations: Vary, but consistently aim to improve access, especially in emerging markets.

What financial trends are observable?

• Revenue forecasts: Compound annual growth rate (CAGR) of 3-5% projected from 2022–2027.
• Pricing pressure: Branded formulations face erosion, with generic prices dropping by 30-50% within five years post-patent expiry.
• Investment in R&D: Focuses on new formulations like extended-release and implantable devices to differentiate products and command premium pricing.

How do future innovations impact market dynamics?

Emerging therapies include:

• Extended-release formulations: Improved symptom control, potentially reducing dosing frequency.
• Gene therapies: Clinical trials ongoing, promising to modify disease progression.
• Device-based treatments: Deep brain stimulation advancements challenge pharmacotherapy's dominance.

These innovations target unmet needs but currently represent a small market share. They could reshape competitive dynamics over the next decade.

What are the key financial implications for stakeholders?

For pharmaceutical companies:

• Generics production remains highly profitable but squeezes margins of branded products.
• Investment in biosimilars and new delivery systems can create premium products.
• Patent litigation and settlements influence market share and revenue stability.

For investors:

• Stable cash flows from established brands offer dividend potential.
• Growth opportunities in emerging markets and R&D pipeline investments carry high risk and potential reward.
• Market saturation and pricing pressures necessitate careful portfolio management.

Summary of market drivers and constraints

Drivers	Constraints
Growing PD prevalence	Patent cliffs leading to generic competition
New formulations and delivery systems	Pricing regulations suppress branded drug margins
Increasing healthcare access in emerging markets	Competitive innovation reducing market share

---

Key Takeaways

• Demand for Carbidopa/Levodopa is sustained by PD prevalence growth.
• Patent expiries have expanded generic availability, pressuring prices.
• Market growth is driven by new formulations and expanding geographic access.
• Innovation in drug delivery and disease-modifying therapies could alter competitive dynamics.
• Financial prospects depend on balancing patent protection, generics competition, and R&D investments.

---

FAQs

Q1: What factors most influence the pricing of Carbidopa/Levodopa?
Patent expiration, market competition, regulatory policies, and payer negotiations primarily determine pricing.

Q2: How do emerging markets affect the market for this drug?
Increased healthcare access and government programs expand demand, providing growth opportunities despite pricing challenges.

Q3: What is the impact of biosimilars and generics on the market?
They significantly lower prices and margins, shifting revenue from branded to generic producers.

Q4: Are new formulations replacing traditional Carbidopa/Levodopa?
Not yet, but extended-release formulations and implantable devices show potential for higher adoption.

Q5: What are the main risks for pharmaceutical companies in this market?
Patent expiration, market saturation, regulatory changes, and rapid innovation reducing product relevance.

---

References

1. Parkinson’s Foundation. Parkinson’s Disease Facts & Figures (2022).
2. IQVIA. The Global Use of Medicines in 2022.
3. EvaluatePharma. 2022 World Preview: Outlook to 2027.
4. FDA. Drug Approvals and Regulatory News (2022).
5. PubMed. Clinical trials on advanced PD treatments (2022).